Here are today's top Wall Street analyst ratings where finbox.io's unbiased fair value estimates support the recommendation.
Top Upgrades and Buy Ratings
Mizuho raised its price target on Jazz Pharmaceuticals (Nasdaq:JAZZ) from $127 to $152 per share and reiterated its Buy rating. Eight valuation models imply an even higher fair value estimate of $180 per share representing 34% upside.
Berenberg Bank reiterated Astrazeneca (LSE:AZN) at Buy. Eleven valuation models imply that shares have nearly 30% upside.
Evercore reiterated Mobileye (NYSE:MBLY) at Buy along with a $60 price target. Our fair value estimate is slightly lower at $56.65 implying shares are over 20% undervalued.
Jefferies Group reiterated T-Mobile (Nasdaq:TMUS) at Buy. The rating is generally supported by the company's fundamentals.
Wedbush and Feltl & Co downgraded Popeyes Louisiana Kitchen (Nasdaq:PLKI) following news that the chicken-centric fast food chain agreed to be acquired by Burger King parent Restaurant Brands (NYSE:QSR). Shares appear to be trading at a large premium on a standalone basis.
Jefferies Group, Drexel Hamilton and William Blair all downgraded Lumos Networks (Nasdaq:LMOS) following news that the company had agreed to be acquired by alternative investment firm EQT Infrastructure. Seven valuation models imply the stock is 30% overvalued on a standalone basis.
Royal Bank Of Canada lowered its price target on Flowserve (NYSE:FLS) from $44 to $43 per share and kept its Underperform rating. Our cash flow models imply an even lower fair value estimate of approximately $39 per share.
Get Started Now!
photo credit: FBTimeLineCover